You are here

LC-MS System to Determine the Molecular Mass of Synthesized Heparan and Chondroitin Sulfate Oligosaccharides

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 4R42GM128484-02
Agency Tracking Number: R42GM128484
Amount: $1,599,559.00
Phase: Phase II
Program: STTR
Solicitation Topic Code: 300
Solicitation Number: PA18-591
Solicitation Year: 2018
Award Year: 2019
Award Start Date (Proposal Award Date): 2018-12-01
Award End Date (Contract End Date): 2020-11-30
Small Business Information
Chapel Hill, NC 27599-0001
United States
DUNS: 078778864
HUBZone Owned: N
Woman Owned: N
Socially and Economically Disadvantaged: Y
Principal Investigator
 (919) 977-1083
Business Contact
Phone: (919) 302-6489
Research Institution
United States

 Nonprofit college or university

This fast-track STTR application proposes to synthesize structurally defined heparan
sulfate and chondroitin sulfate oligosaccharides for biological research. Glycan
Therapeutics is a biotech company specialized in synthesizing sulfated carbohydrates
using innovative enzyme-based methods. This proposal is focused on the synthesis of
large authentic oligosaccharides in the size range of 10-mers to 16-mers, as well as
ultra-large click oligosaccharides in the size range of 30 saccharide residue long. A
highly experienced research team, including Dr. Yongmei Xu (University of North
Carolina), Dr. Robert Linhardt (Rensselaer Polytechnic Institute), and Dr. Vijay
Pagadala (Glycan Therapeutics), will carry out the study. Heparan sulfate and
chondroitin sulfate are members of the glycosaminoglycan family present in large
quantities on mammalian cell surfaces and in the extracellular matrix, displaying a wide
range of biological functions. This proposal is designed to serve two purposes: (i) to
develop a reliable and cost-effective method to synthesize structurally defined heparan
sulfate and chondroitin sulfate oligosaccharides and structurally controlled
polysaccharides to support glycoscience research; and (ii) to simplify this technology to
allow nonglycoscientists to utilize this technology in a standard biochemistry laboratory
setting. We anticipate that this proposal will provide valuable technical advances to
glycoscience research. Three specific aims are proposed: Aim 1 is to synthesize a
library of structurally defined heparan sulfate oligosaccharides with a size of up to
hexadecasaccharides (16-mers); Aim 2 is to develop novel chemoenzymatic methods to
synthesize chondroitin sulfate oligosaccharides; Aim 3 is to prepare structurally
controlled click heparan sulfates and chondroitin sulfate oligosaccharides.The purpose of this supplementary application is to request funding to purchase a pre-
owned LC-MS system at the total cost of $119,500. This instrument will be utilized to
determine the molecular mass of the synthesized heparan sulfate and chondroitin
sulfate oligosaccharides. The project for the synthesis of heparan sulfate and
chondroitin sulfate is currently under the support of NIGMS STTR grant (Dr. Yongmei
Xu, 1R42GM128484-02). The LC-MS instrument will allow us to analyze the
synthesized oligosaccharides during the reaction, avoiding the purification and desalting
steps. This capability will significantly increase our speed and throughput for the
sample analysis, which is extremely important for completing the proposed
oligosaccharide library synthesis.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government